Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider Trading: Samuel Isaly’s Orbimed Advisors is Selling $ANTH

Samuel Isaly’s Orbimed Advisors filed for its recent insider sales in Anthera Pharmaceuticals Inc (ANTH) on November 18th. According to the filing, Orbimed Advisors sold 52 thousand shares in ANTH from November 16 to 18. The average selling price per share was about $6.76. After that Orbimed Advisors still remains 2.89 million shares in its ANTH position, corresponding to a 6.88% activist stake ownership. This is the second insider filing in ANTH revealed by Orbimed Advisors after the third quarter. Before November 16th, Orbimed Advisors sold 60 thousand shares at about $6.94 per share. Orbimed Advisors did not change its position during the third quarter when the firm took 3 million shares in the stock. ANTH has gained 24% so far in 2011. The stock is now trading at $6.05.

Fourteen hedge funds were bullish about ANTH based on their positions in the second quarter. Beside Orbimed Advisors’ largest stake among the hedge funds, Jacob Gottlieb’s Visium Asset Management increased its position by 19% to 1.91 million shares. Roberto Mignone’s Bridger Management took the third with its 1.33 million shares position.


Orbimed is the world’s largest healthcare-dedicated investment firm. The firm has with approximately $5 billion in assets under management. The firm was founded in 1989 with a vision to invest across the spectrum of healthcare companies. The firm manages a series of venture capital funds and public equity investment funds.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company. The company focuses on developing and commercializing products to treat serious diseases including cardiovascular and autoimmune diseases. The company had one Phase 3 clinical program and two Phase 2 clinical programs as of December 2010. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!